Cerebral embolization in asymptomatic versus symptomatic patients after carotid stenting  by Tulip, Hans H. et al.
From the Southern Association for Vascular Surgery
Cerebral embolization in asymptomatic versus
symptomatic patients after carotid stenting
Hans H. Tulip, MD,a Eric B. Rosero, MD,a Adriana J. Higuera, MD,b Adriana Ilarraza, BS,a
R. James Valentine, MD,a and Carlos H. Timaran, MD,a Dallas, Tex
Background: Previous studies have investigated the development of new ischemic brain lesions on diffusion-weighted
magnetic resonance imaging (DW-MRI) after carotid artery stenting (CAS). The rate of ischemic brain injury after CAS
for asymptomatic stenosis has not been extensively studied but is presumed to be less likely than in symptomatic patients.
This study assessed the occurrence of cerebral embolization after CAS for asymptomatic vs symptomatic carotid stenosis.
Methods: During an 18-month period, 40 patients undergoing CAS under filter embolic protection were prospectively
evaluated. Transcranial Doppler (TCD) during CAS and preprocedural and 24-hour postprocedural DW-MRI were used
to assess cerebral embolization. Univariate and nonparametric analyses were used to compare differences in cerebral
embolization after CAS in asymptomatic and symptomatic patients.
Results: CAS was performed for 23 asymptomatic (58%) and 17 symptomatic (42%) carotid stenoses. The median
microembolic counts detected by TCD were 285 (interquartile range [IQR], 182-376) for asymptomatic and 313 (IQR,
170-426) for symptomatic carotid stenosis (P  .6). DW-MRI was available for assessment in 20 asymptomatic and 14
symptomatic patients. New acute cerebral emboli detected with DW-MRI occurred in 10 asymptomatic (50%) and 7
symptomatic patients (50%) undergoing CAS (P  .9). The ipsilateral and total median number of DW-MRI lesions
between groups were not statistically significantly different at, respectively, 1 (IQR, 0-2.5) and 1.5 (IQR, 0-3) for
asymptomatic vs 0.5 (IQR, 0-2) and 0.5 (IQR, 0-3) for symptomatic carotid stenosis (P> .5). One asymptomatic patient
sustained a minor stroke after CAS. No new neurologic events occurred in symptomatic patients. The 30-day
stroke-death rate was 2.5% in this series.
Conclusions: Cerebral embolization, as detected by TCD and DW-MRI, occurs with a similar frequency after CAS for
asymptomatic and symptomatic carotid stenosis. Because postprocedural ischemic brain injury occurs in approximately
half of asymptomatic patients, the safety of CAS under filter embolic protection for asymptomatic carotid stenosis is
uncertain and warrants further study. (J Vasc Surg 2012;56:1579-84.)
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CCarotid artery stenting (CAS) with embolic protection
devices is an established treatment option for patients pre-
senting with asymptomatic and symptomatic carotid artery
stenosis.1-3 Its application has been particularly useful in
patients with significant comorbidities or with a hostile
neck from previous surgical procedures or radiation.4 The
major complication of carotid interventions is embolization
of plaque debris to the brain and subsequent stroke.5 New
ischemic brain lesions can occur after CAS or carotid end-
arterectomy (CEA).5-8
The significance of these microemboli, as detected
by intraoperative transcranial Doppler (TCD) evaluation
and preprocedural and postprocedural diffusion-weighted
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http://dx.doi.org/10.1016/j.jvs.2012.06.074agnetic resonance imaging (DW-MRI), has not been
stablished. Previous studies have focused on comparing
EA and CAS and have included primarily symptomatic
atients, demonstrating increased rates of embolization
uring CAS compared with CEA.9 Among symptomatic
atients, microemboli presumably result from atheroscle-
otic plaques that are less stable andmore likely to embolize
uring the intervention. Among asymptomatic patients,
he incidence of periprocedural and postprocedural sub-
linical cerebral embolization, as detected with TCD and
W-MRI, has not been established, although a recent
eta-analysis found no statistically significant difference in
he frequency of new DW-MRI lesions among asymptom-
tic vs symptomatic patients after CAS.9
This study assessed the specific incidence of subclinical
erebral embolization detected by TCD and DW-MRI
fter CAS according to symptomatic status. Because the
ate of ischemic brain injury after CAS for asymptomatic
tenosis is presumed to be less than after CAS for symptom-
tic lesions, this study specifically compared the occurrence
f cerebral embolization after CAS for asymptomatic vs
ymptomatic carotid stenosis.
ETHODS
During an 18-month period, 40 men with severe ca-
otid stenosis and at high risk or with contraindications for
EA were enrolled in a randomized clinical trial whose
rimary end point was to compare the degree of subclinical
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December 20121580 Tulip et alcerebral embolization after CAS between open-cell and
closed-cell stents (http://ClinicalTrials.gov identifier:
NCT00830232).10 One of the secondary end points of the
trial was to assess the effects of symptomatic status on
cerebral embolization, which is the focus of this study. The
North Texas Veterans Affairs Administration and the Uni-
versity of Texas Southwestern Medical Center Institutional
Review Boards reviewed and approved the study.
Patients with carotid stenosis were considered symp-
tomatic if they presented with a history of stroke, amaurosis
fugax, or transient ischemic attacks (TIAs) involving the
ipsilateral carotid territory that occurred 180 days of the
initial evaluation. Patients with carotid stenosis that did not
meet the definition for symptomatic carotid stenosis were
considered asymptomatic, including patients with no neu-
rologic symptoms referable to the cerebral hemisphere
ipsilateral to the carotid stenosis or a history of previous
neurologic events without subsequent event 180 days.
Patients with atypical or nonfocal neurologic symptoms (ie,
dizziness, confusion) or vertebrobasilar symptoms were
also deemed asymptomatic with respect to their carotid
disease.
Clinical, procedural, and outcome variables were de-
fined according to the Society for Vascular Surgery report-
ing standards for carotid interventions.11 Indications for
CAS included moderate (50%) symptomatic carotid ste-
nosis or severe (80%) asymptomatic carotid stenosis de-
termined with duplex ultrasound imaging and confirmed
during the procedure with digital subtraction angiography.
Symptomatic status was not a significant cofactor on
the inclusion or exclusion of patients in the original ran-
domized trial that assessed the effects of stent design.10 The
number of symptomatic and asymptomatic patients in-
cluded in the trial and in the current study was, therefore, a
random result. Measurements of angiographic carotid ste-
nosis (percentage by diameter) were performed according
to North American Symptomatic Carotid Endarterectomy
(NASCET) methodology.12
All CAS procedures were performed under local anes-
thesia and intravenous sedation, as required, through ret-
rograde femoral access. Procedural details and CAS proto-
cols at our institutions followed techniques described in
detail before.13 Neurologic evaluation was performed us-
ing the National Institutes of Health Stroke Scale (NIHSS)
by trained and certified personnel before the procedure,
before discharge, and at the 30-day follow-up visit.
All patients received dual-antiplatelet therapy with as-
pirin and a thienopyridine before the procedure and post-
operatively. CAS procedures were performed using a fixed
angiographic unit (Allura Xper FD20; Philips, Bothell,
Wash). To avoid variability in the degree of subclinical
cerebral embolization related to the type of embolic pro-
tection used, all procedures were performed with the Ac-
cunet filter device (Abbott Vascular, Santa Clara, Calif).
Open-cell (Acculink carotid stent; Abbott Vascular) and
closed-cell stents (Xact carotid stent; Abbott Vascular) were
both used. bPredilatation was selectively performed using rapid-
xchange balloons, 4 mm in diameter and 20 to 40 mm in
ength. Postdilatation was selectively performed using
onorail 5- or 5.5-mm balloons if residual stenosis after
tent placement was 20% to 30%. Completion angio-
rams, including cervical and cerebral views, were routinely
btained.
Plaque composition was assessed using virtual histol-
gy intravascular ultrasound (VH-IVUS) images, which
ere obtained using a 2.9F, 20-MHz Eagle Eye Gold
atheter (Volcano Corp, Rancho Cordova, Calif) with an
ncorporated 20-MHz phased-array transducer. Plaques
ere interrogated with the IVUS catheter beginning from
he distal vessel, at least 10 mm distal to the culprit lesion,
nd progressing in a retrograde direction to the most distal
ommon carotid artery free of disease. VH analysis was
erformed in an automated fashion using Volcano S5 soft-
are (Volcano Corp).14
DW-MRI scans of the brain were obtained immediately
efore CAS and 18 to 24 hours after the procedure. Stan-
ard head coils on 1.5 T Siemens Avanto or Magnetom
onata scanners (Siemens, Erlangen, Germany) were used.
W-MRI with echo-planar imaging sequence (B0 
000) and fluid-attenuated inversion recovery images were
btained in axial and coronal sections. New ischemic brain
esions on postprocedural DW-MRI images were identified
s focal hyperintense areas with restricted diffusion signal,
hich were confirmed by apparent diffusion coefficient
apping to rule out artifacts. Location ipsilateral or con-
ralateral to the target carotid stenosis and the number of
ew ischemic brain lesions consistent with microemboli
as recorded in all DW-MRI examinations performed.
TCD monitoring was performed using a PMD150-
T3 digital TCD pulsed-wave ultrasound system (Spencer
echnologies, Seattle, Wash) with 2-MHz probes located
ver the temporal bones above the zygomatic arch. Isolated
icroembolic signals (MESs) were identified fromDoppler
pectra according to the criteria given by the Ninth Inter-
ational Cerebral Hemodynamic Symposium Consensus
ommittee.15 The studies were stored on a hard drive and
ere analyzed off-line without the use of the automatic
mboli detection software. If the number of MESs was too
igh to be counted separately, heartbeats withmicroemboli
ere counted as microembolic showers. To avoid confu-
ion, MESs detected during contrast injection were ex-
luded from the analysis. The TCD and DW-MRI studies
ere both assessed by readers blinded to the clinical status,
tent design, and patient outcome.
Continuous variables are expressed as medians and
nterquartile ranges (IQR) and categoric variables as rela-
ive frequencies. The Mann-Whitney U test and 2 contin-
ency table analysis or Fisher exact test, as indicated, were
sed to compare continuous and categoric variables, re-
pectively. The association between symptomatic status and
he frequency of TCD-detected MES counts during CAS
nd the incidence and location of acute postprocedural
mbolic lesions detected with DW-MRI were assessed with
ivariate statistical tests. Statistical significance was defined
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Volume 56, Number 6 Tulip et al 1581at P  .05. SAS 9.2 (SAS Institute, Cary, NC) and Med-
Calc 12.1.4.0 (MedCalc Software, Mariakerke, Belgium)
software programs were used for data analyses.
RESULTS
CAS was performed in 23 asymptomatic (58%) and 17
symptomatic patients (42%) with carotid stenosis. No sig-
nificant differences in patient characteristics, indication for
CAS, or plaque composition as assessed by VH-IVUS were
observed between patient groups, although a trend was
found for a higher frequency of chronic renal insufficiency
in symptomatic patients (29%) than in asymptomatic pa-
tients (4%; P  .07; Table). Tandem lesions were not seen
in any patient. Technical success with residual stenosis
30% was achieved in all cases. Stent design did not differ
among groups. Closed-cell stents were used in 60% of
asymptomatic patients and in 55% of symptomatic patients
Table. Baseline characteristics and plaque composition of
the study population according to symptomatic status
Characteristic
Asymptomatic
(n  23)
Symptomatic
(n  17) Pa
Age, median (IQR)
years
69.2 (60-75) 63.4 (59.3-73.7) .45
Male sex, No. 100 100
Risk factors, % of
patients
Hypertension 83 88 .99
Diabetes 44 53 .75
Dyslipidemia 87 83 .99
Tobacco smoking 48 29 .35
Treatment with
statins
83 77 .71
Congestive heart
failure
9 17 .63
Coronary artery
disease
39 53 .38
COPD 13 24 .43
Chronic renal
insufficiency
4 29 .07b
Anatomic
characteristics, %
Contralateral
occlusion
17 24 .70
High carotid lesion
(above C2)
35 18 .30
Hostile neckc 26 24 .99
Plaque composition,
median mm3d
Plaque burden 170 301 .85
Fibrous 88 138 .50
Fibrofatty 28 33 .99
Dense calcium 10.4 9.8 .77
Necrotic core 27.5 38.6 .92
COPD, Chronic obstructive pulmonary disease; IQR, interquartile range.
aFisher exact test, 2 contingency table analysis, and Wilcoxon rank sum test
for independent samples were used for statistical analysis, as appropriate.
bFisher exact test.
cPrevious endarterectomy, radical neck dissection, radiation.
dPlaque composition was determined by virtual histology intravascular
ultrasound and assessed over the entire length of the lesion.(P  .99). One asymptomatic patient sustained a minor otroke after CAS, but no new neurologic events occurred in
ymptomatic patients. The 30-day stroke-death rate was
.5% in this series.
TCD monitoring interpretable results were available in
ll patients. Subclinical cerebral embolization detected by
CD monitoring was not significantly different for CAS
rocedures performed for asymptomatic vs symptomatic
arotid stenoses (Fig 1). The total ipsilateral median micro-
mbolic counts detected by TCD were 285 (IQR, 182-
76) for asymptomatic and 313 (IQR, 170-426) for symp-
omatic carotid stenosis (P  .6). The total median
psilateral microembolic showers were 26 (IQR, 14-43) for
symptomatic and 25 (IQR, 19-42) for symptomatic pa-
ients (P  .68).
DW-MRI scans were not available in three symptom-
tic and in three asymptomatic patients because the patients
efused to undergo postprocedural MRI scans due to claus-
rophobia or because the images could not be interpreted
ue to distortions by metal or severe motion artifacts. New
cute cerebral emboli detected with DW-MRI occurred in
0 asymptomatic (50%) and 7 symptomatic patients (50%)
ndergoing CAS (P .9). The ipsilateral and total median
umber of DW-MRI lesions between groups was not sta-
istically significantly different at, respectively, 1 (IQR,
-2.5) and 1.5 (IQR, 0-3) for asymptomatic vs 0.5 (IQR,
-2) and 0.5 (IQR, 0-3) for symptomatic carotid stenosis
P  .5; Figs 2 and 3).
All patients with positive DW-MRI after CAS were
symptomatic and remained free of neurologic events at 30
ays. Conversely, a minor ischemic hemispheric stroke
ig 1. The median number of microembolic signals (MES) doc-
mented by transcranial Doppler (TCD) monitoring was not
ignificantly different after carotid artery stenting (CAS) in asymp-
omatic and symptomatic patients. The horizontal line in the
iddle of each box indicates themedian; the top and bottom borders
f the box mark the 75th and 25th percentiles, respectively; the
hiskers mark the 95% confidence interval; and the open circle
hows an outlier (P  .6).ccurred 3 days after CAS in one asymptomatic patient
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December 20121582 Tulip et alwhose postprocedural DW-MRI was negative for new le-
sions. Carotid duplex ultrasound imaging, computed to-
mography, and MR angiography revealed a patent stent
without restenosis and intracranial arterial stenosis as the
possible cause of the stroke. A TIA occurred 19 days after
CAS in one symptomatic patient who refused the postpro-
Fig 2. New ipsilateral acute cerebral emboli detected with
diffusion-weighted magnetic resonance imaging (DW-MRI)
were not significantly different between asymptomatic and
symptomatic patients undergoing carotid artery stenting (CAS).
The horizontal line in the middle of each box indicates the
median; the top and bottom borders of the box mark the inter-
quartile range (75th and 25th percentiles), respectively; the
whiskers mark the 95% confidence interval; and the open circle
and black square show the outliers (P  .9).
Fig 3. The total median number of lesions documented by
diffusion-weighted magnetic resonance imaging (DW-MRI) was
not statistically significantly different, at 1.5 (interquartile range
[IQR], 0-3) for asymptomatic vs 0.5 (IQR, 0-3) for symptomatic
carotid stenosis. The horizontal line in the middle of each box
indicates the median; the top and bottom borders of the box mark
the interquartile range (75th and 25th percentiles), respectively;
the whiskers mark the 95% confidence interval; and the open circle
and black square show the outliers (P  .5).cedural DW-MRI. iISCUSSION
The results of this observational study indicate that
erebral embolization, as detected by TCD and DW-MRI,
ccurs with similar frequency during CAS for symptomatic
nd asymptomatic lesions. The clinical significance of these
ubclinical events is still unknown. Our data, however,
uggest that the utility of CAS for asymptomatic lesions
eeds further assessment given the potential ischemic brain
njury that may occur in up to half of the patients undergo-
ng the procedure. Unless cerebral embolization may be
educed or completely eliminated, our data suggest that
urther investigation is required to identify those asymp-
omatic lesions prone to embolization after best medical
herapy has been instituted. These lesions may also be
etter treated with CEA, intensive medical therapy alone,
r with CAS with improved embolic protection or new
tent designs.
Cerebral embolization, whether clinical or subclinical,
hould be considered a complication of any intervention for
arotid stenosis because stroke prevention is the primary
oal of any carotid procedure.7,9 Although previous studies
ave demonstrated subclinical cerebral embolization by
CD and DW-MRI after CAS, this study directly com-
ared the rate of subclinical embolization between asymp-
omatic and symptomatic lesions. Given our findings, the
ndovascular treatment of asymptomatic carotid stenosis
ust be approached with caution. The rate of cerebral
mbolization demonstrated in this study is of particular
oncern in light of the low embolic potential of asymptom-
tic lesions when treated with intense medical therapy or
ven with CEA.9
The clinical significance of new cerebral ischemic le-
ions that occur in the periprocedural period after carotid
nterventions remains unknown. These lesions, however,
ppear to have a negligible effect on long-term neurologic
utcomes or clinically relevant cognitive performance.8,9
egardless of their clinical manifestations, new brain lesions
o represent cerebral injury and should be eliminated, if
ossible, after interventions for asymptomatic lesions. Sev-
ral studies have demonstrated a decreased incidence of
erebral embolization documented by DW-MRI in pa-
ients treated with CEA compared with CAS.9 Given the
ower incidence of stroke in asymptomatic disease, best
edical therapy alone, CEA, or CAS using proximal bal-
oon occlusion or flow reversal may currently provide a safer
lternative to CAS under filter embolic protection for
symptomatic patients with lesions prone to embolization.
Unfortunately, as reported in our previous publica-
ion,10 closed-cell stents did not reduce cerebral emboliza-
ion after CAS among symptomatic or asymptomatic pa-
ients and, therefore, cannot be advocated as a means to
meliorate the degree of ischemic brain injury related
o this intervention. Similarly, VH-IVUS was not helpful to
etermine the embolic potential of plaque composition
nd, at this point, cannot be recommended as a method to
etermine vulnerable plaques.16 Although methods to
dentify the embolic potential of carotid lesions are not
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terization of plaque composition may help select the subset
of asymptomatic patients who would benefit most from
specific interventions.17-20
The role of carotid intervention for asymptomatic ca-
rotid stenosis has been questioned in recent years given the
advances in medical therapy and reduced cardiovascular
events.21 Annual stroke rates as low as 0.3% to 0.5% with
medical therapy alone were also recently reported, which
are substantially lower than those from initial landmark
trials that defined the role of CEA for the treatment of
carotid stenosis.21-26 Moreover, maximal medical therapy
alone recently demonstrated superior results than angio-
plasty and stenting for the treatment of intracranial carotid
stenosis in the Stenting and Aggressive Medical Manage-
ment for Preventing Recurrent Stroke in Intracranial Ste-
nosis (SAMMPRIS) trial.27 Although such intense medical
therapy has not been compared directly with carotid inter-
ventions for the treatment of extracranial carotid disease,
the evidence from the SAMMPRIS trial27 adds to the
assumption that current medical therapy has likely altered
the medical natural history of carotid artery stenosis.
The landmark studies comparing carotid intervention
with medical therapy occurred when medical therapy con-
sisted primarily of aspirin.12,28 In the era of statin therapy,
more effective blood pressure control, and multiple modal-
ities of antiplatelet therapy, these medical treatments may
have been able to significantly decrease the risk of stroke for
any given lesion. This has been indirectly demonstrated by
the reduction in MES by TCD in comparative studies
before and after intensive medical therapy has been insti-
tuted,23 which ought to be considered before intervention.
Alternatively, the safety and efficacy of CAS may be en-
hanced with different or additional types of embolic pro-
tection or further developments in stent design. Obviously,
additional investigation is needed to demonstrate that these
adjunctive techniques result in reduced cerebral emboliza-
tion after CAS.
Several important limitations of this observational
study should be acknowledged: First, this study includes a
small sample size that may not account for differences in
cerebral embolization that would become apparent with a
larger cohort.
Second, although no significant differences between
groups were observed, a multivariate analysis to determine
if symptomatic status influenced cerebral embolization af-
ter adjusting for the effects of other covariates was not
feasible given the small sample size and limited number of
positive events.
Third, the applicability of the results of this study to
standard-risk patients is not definitive because the results of
CAS may vary according to medical and anatomic risk.
Finally, albeit frequently used, only one type of embolic
protection device was used in this study. Further investiga-
tions are necessary regarding the effects of other types of
embolic protection and stent design, apart from stent-cell
configuration or area, on cerebral embolization. Moreover,
further characterization of the microembolic events andew ischemic lesions after CAS, as well as a comparison
ith best medical therapy, are required before clinical rec-
mmendations can be made.
ONCLUSIONS
Cerebral embolization occurs with similar frequency
uring CAS in symptomatic as well as in asymptomatic
atients. Although the clinical significance of these new
mbolic findings is unknown, they do represent cerebral
njury. This observational study questions the safety of CAS
nder filter embolic protection for asymptomatic carotid
tenosis because new ischemic brain injury occurs in ap-
roximately half of asymptomatic patients.
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Dr Charles Sternbergh, III (NewOrleans, La). Dr Tulip and
colleagues bring us important and timely data today, emblematic
of the insightful research we have come to expect from the vascular
group at University of Texas Southwestern. In this study, 40
patients underwent carotid artery stenting (CAS), 23 for asymp-
tomatic and 17 for symptomatic disease. Subclinical evidence of
cerebral emboli was studied with intraprocedural transcranial
Doppler and diffusion-weighted magnetic resonance imaging
(DW-MRI) scans obtained preoperatively and postoperatively.
If this study cohort and design sounds familiar to this audi-
ence, it should. At this meeting in January 2011, the identical
patient cohort was presented, with the same outcome parameters
of transcranial Doppler hits and new DW-MRI brain lesions. That
randomized, prospective trial compared open-cell vs closed-cell
stents, and no difference between groups was seen in subclinical
emboli.1
Today, the study instead provides the subcohort data on
asymptomatic vs symptomatic patients. A sobering 50% rate of
ischemic brain injury was seen on DW-MRI in both groups. If the
late John Porter were still with us today, his Yearbook of Vascular
Surgery might have bestowed the authors with the dreaded
“salami-slicer” award for parsing out pieces of data into multiple
publications instead of in a single communication.
But here’s the thing: I understand why the authors chose not
to include these patient cohorts in the original publication. The
impact of the data might have been lost, or at least diminished.
Although the long-term clinical significance of these DW-MRI
lesions is uncertain, a 50% rate of acute brain injury, even if
clinically asymptomatic, cannot be a good thing. I would not wish
my mother to be subjected to such odds—gee, not even mylter-protected CAS in asymptomatic patients should be per-
ormed. I have two questions for the authors:
First, based on the presented data, do the authors feel it is
thical to offer CAS with filter protection to a patient with asymp-
omatic disease?
Second, flow-reversal or flow cessation protection has shown
romise in decreasing subclinical cerebral emboli in symptomatic
atients undergoing CAS. Has your group shifted to such embolic
rotection techniques, even in asymptomatic patients?
Dr Hans H. Tulip. Thank you, Dr Sternberg, I appreciate
our questions. In answer to your first question, I do feel that CAS
s safe for patients with asymptomatic carotid artery stenosis based
n current data. Because we do not know the effects of these silent
erebral emboli, carotid endarterectomy should be considered in
atients who are fit for open surgery. From here, we need to focus
ur efforts on identifying the subset of asymptomatic patients that
re more likely to benefit from surgery. Once this group is identi-
ed, carotid stenting and endarterectomy will provide maximal
enefit at acceptable risk to these patients. In answer to your
econd question, we are beginning to enroll patients in an Ameri-
an Heart Association–funded trial to determine the role for prox-
mal balloon occlusion and flow reversal compared with filter
mbolic protection devices to determine whether this reduces the
ncidence of these subclinical cerebral embolization and neuro-
ogic events.
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